Daily resveratrol consumption supports cardiovascular health in overweight adults, meta-analysis shows
Highlights
- Meta-analysis of 21 randomized, controlled trials
- Resveratrol significantly (P<.05) lowers total cholesterol, systolic blood pressure, and fasting glucose
- Subgroup analysis show significant reductions in total cholesterol, blood pressure, glucose, and insulin in subjects ingesting higher dosages (at least 300 mg/day)
Summary
This meta-analysis was designed to evaluate the effects of resveratrol consumption on risk markers of cardiovascular health in overweight/obese people.
Multiple literature databases (e.g., PubMed, Embase, Cochrane) were systematically searched for randomized, controlled trials that estimate the effects of resveratrol intake in overweight or obese individuals without language and age restrictions from the earliest available online indexing year to January 2016. The search was restricted to clinical trials in humans.
A total of 21 studies met the inclusion criteria. Resveratrol dosages ranged from 8 mg/day to 3,000 mg/day; study durations ranged from one to 6 months. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI), and heterogeneity was assessed with the I-squared test. Publication bias and subgroup analyses were also performed.
Based on weighted mean differences (WMD), results indicate resveratrol significantly (P<.05) lowered total cholesterol (WMD, -0.19 mmol/L), systolic blood pressure (WMD, -2.26 mmHg), and fasting glucose (WMD, -0.22 mmol/L). Heterogeneity was noted for these outcomes (35.6%, 38.7% and 71.4%, respectively). Subgroup analysis showed significant reductions in total cholesterol, systolic blood pressure, diastolic blood pressure, glucose, and insulin in subjects ingesting higher dosages of resveratrol (at least 300 mg/day).
These findings suggest that daily resveratrol intake (at least 300 mg/day) supports cardiovascular health in overweight/obese individuals.
